Literature DB >> 19508237

A generalized estimator of the attributable benefit of an optimal treatment regime.

Jason Brinkley1, Anastasios Tsiatis, Kevin J Anstrom.   

Abstract

For many diseases where there are several treatment options often there is no consensus on the best treatment to give individual patients. In such cases, it may be necessary to define a strategy for treatment assignment; that is, an algorithm that dictates the treatment an individual should receive based on their measured characteristics. Such a strategy or algorithm is also referred to as a treatment regime. The optimal treatment regime is the strategy that would provide the most public health benefit by minimizing as many poor outcomes as possible. Using a measure that is a generalization of attributable risk (AR) and notions of potential outcomes, we derive an estimator for the proportion of events that could have been prevented had the optimal treatment regime been implemented. Traditional AR studies look at the added risk that can be attributed to exposure of some contaminant; here we will instead study the benefit that can be attributed to using the optimal treatment strategy. We will show how regression models can be used to estimate the optimal treatment strategy and the attributable benefit of that strategy. We also derive the large sample properties of this estimator. As a motivating example, we will apply our methods to an observational study of 3856 patients treated at the Duke University Medical Center with prior coronary artery bypass graft surgery and further heart-related problems requiring a catheterization. The patients may be treated with either medical therapy alone or a combination of medical therapy and percutaneous coronary intervention without a general consensus on which is the best treatment for individual patients.

Entities:  

Mesh:

Year:  2009        PMID: 19508237      PMCID: PMC2891886          DOI: 10.1111/j.1541-0420.2009.01282.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  8 in total

Review 1.  A review of adjusted estimators of attributable risk.

Authors:  J Benichou
Journal:  Stat Methods Med Res       Date:  2001-06       Impact factor: 3.021

2.  Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures.

Authors:  Babette A Brumback; Miguel A Hernán; Sebastien J P A Haneuse; James M Robins
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

3.  Standard errors for attributable risk for simple and complex sample designs.

Authors:  Barry I Graubard; Thomas R Fears
Journal:  Biometrics       Date:  2005-09       Impact factor: 2.571

4.  The occurrence of lung cancer in man.

Authors:  M L LEVIN
Journal:  Acta Unio Int Contra Cancrum       Date:  1953

5.  Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods.

Authors:  S Yusuf; J Wittes; K Bailey; C Furberg
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

6.  Using observational data from registries to compare treatments: the fallacy of omnimetrics.

Authors:  S B Green; D P Byar
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

7.  Incidence and predictors of sudden cardiac death in patients with diastolic heart failure.

Authors:  Sana M Al-Khatib; Linda K Shaw; Christopher O'Connor; Melissa Kong; Robert M Califf
Journal:  J Cardiovasc Electrophysiol       Date:  2007-09-10

8.  Testing for qualitative interactions between treatment effects and patient subsets.

Authors:  M Gail; R Simon
Journal:  Biometrics       Date:  1985-06       Impact factor: 2.571

  8 in total
  19 in total

1.  Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.

Authors:  Jared C Foster; Jeremy M G Taylor; Niko Kaciroti; Bin Nan
Journal:  Biostatistics       Date:  2014-11-13       Impact factor: 5.899

2.  Robustifying Trial-Derived Optimal Treatment Rules for A Target Population.

Authors:  Ying-Qi Zhao; Donglin Zeng; Catherine M Tangen; Michael L LeBlanc
Journal:  Electron J Stat       Date:  2019-04-30       Impact factor: 1.125

3.  An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects.

Authors:  Jessie K Edwards; Stephen R Cole; Catherine R Lesko; W Christopher Mathews; Richard D Moore; Michael J Mugavero; Daniel Westreich
Journal:  Am J Epidemiol       Date:  2016-07-28       Impact factor: 4.897

4.  Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective.

Authors:  Xiaofei Bai; Anastasios A Tsiatis; Wenbin Lu; Rui Song
Journal:  Lifetime Data Anal       Date:  2016-08-01       Impact factor: 1.588

5.  Variable selection for optimal treatment decision.

Authors:  Wenbin Lu; Hao Helen Zhang; Donglin Zeng
Journal:  Stat Methods Med Res       Date:  2011-11-23       Impact factor: 3.021

6.  Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.

Authors:  Holly Janes; Marshall D Brown; Michael R Crager; Dave P Miller; William E Barlow
Journal:  Contemp Clin Trials       Date:  2017-08-14       Impact factor: 2.226

7.  Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.

Authors:  Chaeryon Kang; Holly Janes; Parvin Tajik; Henk Groen; Ben Mol; Corine Koopmans; Kim Broekhuijsen; Eva Zwertbroek; Maria van Pampus; Maureen Franssen
Journal:  Stat Med       Date:  2018-02-14       Impact factor: 2.373

8.  Tree-based methods for individualized treatment regimes.

Authors:  E B Laber; Y Q Zhao
Journal:  Biometrika       Date:  2015-07-15       Impact factor: 2.445

9.  A robust method for estimating optimal treatment regimes.

Authors:  Baqun Zhang; Anastasios A Tsiatis; Eric B Laber; Marie Davidian
Journal:  Biometrics       Date:  2012-05-02       Impact factor: 2.571

10.  On Enrichment Strategies for Biomarker Stratified Clinical Trials.

Authors:  Xiaofei Wang; Jingzhu Zhou; Ting Wang; Stephen L George
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.